Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 7/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PGK1 | P00558 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31592017 | 1.00 | TSHR (0.52) | TSHRMAPK1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL864500 | 0.89 | TSHR (0.50) | TSHRMAPK1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL16013560 | 0.89 | TSHR (0.50) | TSHRMAPK1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL1626324 | 0.89 | TSHR (0.50) | TSHRMAPK1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL29721556 | 0.89 | TSHR (0.50) | TSHRMAPK1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL358890 | 0.89 | TSHR (0.50) | TSHRMAPK1ALDH1A1CYP3A4MAPT | |
| Benzene SCHEMBL27763648 | 0.85 | TSHR (0.47) | TSHRMAPK1ALDH1A1CYP3A4TDP1 | |
| SCHEMBL80032 | 0.84 | PPIA (0.47) | TSHRMAPK1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL29586844 | 0.84 | PPIA (0.47) | TSHRMAPK1ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL15798372 | 0.84 | TSHR (0.46) | TSHRMAPK1ALDH1A1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109748885-B | Ceritinib intermediate and preparation method of ceritinib | 新发药业有限公司 | 2020-08-11 | — | — | CN | claimed |
| US-20230219925-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences (CN) | 2023-07-13 | — | — | US | disclosed |
| CN-113912563-A | Benzo five-membered nitrogen heterocyclic compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2022-01-11 | — | — | CN | disclosed |
| CN-109748885-B | Ceritinib intermediate and preparation method of ceritinib | 新发药业有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-109748885-B | Ceritinib intermediate and preparation method of ceritinib | 新发药业有限公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| CN-101665570-B | Method for synthesizing low-chloride polyphenylene sulfide resin | DEYANG KEJI HI TECH MATERIAL CO LTD | 2011-09-14 | — | — | CN | disclosed |
| CN-101679299-A | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| CN-101665570-A | Method for synthesizing low-chloride polyphenylene sulfide resin | DEYANG KEJI HI TECH MATERIAL C | 2010-03-10 | — | — | CN | disclosed |
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
| CN-1016175-B | Imidazoquinoline antithrombin cardiotonic agents | BRISTOL MYERS CO (US) | 1992-04-08 | — | — | CN | disclosed |
| EP-0342532-A1 | Process for the preparation of 4-chloro-2-methyl-5-nitro-phenol | Wella Aktiengesellschaft (DE) | 1989-11-23 | — | — | EP | disclosed |
| CN-86102747-A | The preparation method of imidazoquinoline antithombogehic cardiotonic agents | — | 1987-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | TSHR 4209/4885MAPK1 2649/4885ALDH1A1 45/4885 |
| US-20230219925-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | RORC, RORB, RORA | TSHR 1285/4885MAPK1 2207/4885ALDH1A1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.